NCT06841055: An ongoing trial by Biontech SE
This trial is ongoing. It must report results 3 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06841055 |
|---|---|
| Title | A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 3, 2025 |
| Completion date | Oct. 31, 2028 |
| Required reporting date | Oct. 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 29, 2026 |
| Days late | None |